We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Pediatric Cancer Panel: Move Away from Single-Agent Studies
FDA Pediatric Cancer Panel: Move Away from Single-Agent Studies
In developing future clinical trials, sponsors should consider whether the drug will be intended for use as a single agent or as part of a combination therapy, said members of the Oncologic Drug Advisory Committee’s pediatric subcommittee, in a meeting last month.